Reg 30 NSE LIsting Done

SHUKRA PHARMACEUTICALS LTD. August 14,2026 To, To, The Listing Compliance Department The Listing Department BSE Limited National Stock Exchange of India P. J. Towers, Dalal Street Limited Mumbai - 400001 Exchange Plaza, C-1, Block G Scrip Code: 524632 Bandra Kurla Complex, Bandra (East) Mumbai - 400051 Symbol: SHUKRAPHAR Sub: Disclosure under Regulation 30 of SEB! (Listing Obligations and Disclosure Requirements) Regulations. 2015 - Execution of Term Sheet for proposed Strategic Joint Venture with Borns Medical Robotics Dear Sir/Madam, Pursuant to Regulation 30 read with Schedule lll of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform the Stock Exchanges that Shukra Pharmaceuticals Limited ("Shukra" f "the Company") has entered into a Term Sheet with Borns Medical Robotics Pte Ltd, Singapore("Borns"), for establishing a strategic joint venture for the design, manufacture, distribution and servicing of Al-enabled surgical robotic systems in lndia and the Asia-Pacific region. The k rticulars of the Trerm Sheet are set ou below: Particulars Details Name(s) of the parties with Shukra Pharmaceuticals Limited and Borns Medical Robotics Pte Ltd whom the / proposed Singapore-incorporated holding entity of Borns Medical agreement is Robotics entered into To establish a strategic joint venture for designing, manufacturing, Purpose of distributing and servicing Al-enabled surgical robotic systems in entering into the lndia and the Asia-Pacific region alongwith un-regulated market. agreement After completion of USFDA/CE certificate, entered into the rest of the world. Strategic Joint Venture Term Sheet / Heads of Terms setting out the Nature of principal commercial and legal framework for the proposed joint " agreement venture and the definitive agreements to be executed between the parties. Date of August 13,2026 execution rrN . t )L)?lG tl qq?pt rnl qoTq Regd, Office : 3rd Floori "VEER HOUSE" Opp. WIAA Office, Judges Bunglow Road, BodakdeV Ahmedabad - 380 054. Factory Add. : 795, Rakanpur, Sola-Santej Road, Ta. Kalol, Dist. Gandhinagar - 382721, Gujarat, lndia, Ph. :02764-2863L7 Email : info@shukrapharmaceutica ls.com I Website : www.shukrapharmaceuticals.com SHUKRA PHARMACEUTICALS LTD. Particulars Tenure duration of the agreements. The proposed joint venture is intended to continue agreement subject to the terms of the definitive agreements. Shareholding / ownership Shukra -60% and Borns singapore -4oo/o in the proposed lndian structure joint venture entity, B&S Robotics private Limited. proposed Name of proposed JV B&S Robotics Private Limited ("8&S lndia"), lndia. entity Design, manufacture, distribution and servicing of Al-enabled Nature of surgical robotic systems, together with related instruments, business of JV consumables, software and services, within the approved field of use and territory. Contribution by shukra proposes to contribute capital and provide its sares and Shukra distri bution network, ski I led tea m, ma rket-development ca pa bi r ities, bra ndi n g su pport, i nfrastructu re i n itiatives a nd fi na nci n g ecosystem. Borns proposes to contribute its technology platform and surgicar Contribution by robotic systems, together with relevant technology/lp support, Borns manufacturing know-how and related technical capabilities, in accordance with the definitive agreements. lnitial capital/ The initial paid-up capital of B&S tndia is yet to be determined consideration under the definitive agreements. Subscription is proposed in the ratio of 60:40. Whether the Based on the information presently available, the proposed transaction falls transaction is not a related party transaction. The company shail within retated comply with applicable related party transaction requirements, if party transaction and when applicable. The Term Sheet contemplates, inter alia, incorporation of B&S lndia, incorporation of B&S Singapore Pte. Ltd., investment by Borns Singapore, lP licensing arrangements, transitional supply and Materialterms distribution arrangements, technology transfer/localisation, governance, royalty arrangements, territory and exclusivity, financing, regulatory responsibilities and a potential future demerger/listing pathway. Regd. Office : 3rd Floor, "VEER HOUSE" Opp. WIAA Office, Judges Bunglow Road, Bodakdev, Ahmedabad - 380 054. Factory Add. : 795, Rakanpur, Sola-Santej Road, Ta, Kalol, Dist. Gandhinagar -38272t, Gujarat, lndia, Ph. :02764-2863L7 Email : info@shukrapharmaceutica ls.com I Website : www.shukrapharmaceuticals.com SHUKRA PHARMACEUTICALS LTD. " Particulars Details The proposed Board of B&s lndia is contemprated to comprise five directors, of whom three shall be nominated by shukra and two by Governance Borns Singapore, with governance arrangements to be further documented in the Shareholders' Agreement and Articles of Association. The Term sheet contains binding exclusivity provisions in relation to Exclusivity the surgical robotics category covering the primary Territory, subject to the terms set out therein. The parties intend to enter into definitive agreements incruding the Shareholders' Agreement, Articles of Association, Master lp Definitive Licensing Agreement, Sub-License and Royalty Agreement, " agreements Transitional Supply Distribution Agreement, subscription Agreement, Quality Agreement, Data processing/Al Use and Cybersecurity Agreement and other ancillary agreements. The proposed transaction is subject to, inter alia, establishment of the Borns Singapore entity, completion of mutual due diligence, independent valuation, applicable regulatory/FEMA/FDl Conditions confirmations, necessary corporate approvals, lp due diligence, precedent regulatory pathway confirmation, execution of definitive agreements and other conditions precedent specified in the Term Sheet. Applicable regulatory and statutory approvals/filings, including Regulatory FEMA/FDl-related compliances, CDSCO and other applicable approvals regulatory approvals, and other approvals as may be required, shall be obtained/complied with in accordance with applicable law. The parties have contemplated incorporation of the JV entities and execution of the definitive agreements, with the Long Form Expected timeline Agreements targeted within approximately 120 days from execution of the Term Sheet, subject to satisfaction of the applicable conditions precedent. The Term Sheet itself does not specify any fixed immediate financial commitment or final investment amount by the Company. The lmpact on financial impact, if any, shall be determined upon execution of the financial position definitive agreements and completion of the proposed i nvestment/su bscri ption. Cl N : L2423LGI1993PLC0L9O7 9 Regd. Office : 3rd Floor, "VEER HOUSE' Opp. WIAA Office, Judges Bunglow Road, BodakdeV Ahmedabad - 380 054. Factory Add. :795, Rakanpur, Sola-Santej Road, Ta. Kalol, Dist. Gandhinagar - 38272L, Gujarat, lndia, Ph. :02764-2863L7 Email : info@shukrapharmaceuticals.com I Website : www.shukrapharmaceuticals.com SHUKRA PHARMACEUTICALS LTD. Particulars Details Whether the agreement is in The proposed strategic joint venture is not in the ordinary course of business of the Company and is therefore being disclosed pursuant the ordinary course of to the applicable provisions of Regulation 30 and Schedule lll of the LODR Regulations. business Except for specified provisions relating to confidentiality, exclusivity, costs, governing law and jurisdiction, the Term Sheet is stated to be Termination / non-binding and does not by itself create a contractual obligation binding nature to complete the proposed transaction. The definitive rights and obligations of the parties shall be governed by the Long Form Agreements. The proposed joint venture is intended to create a platform for development of the surgical robotics business in lndia, progressive localisation of manufacturing and expansion into the APAC region. The Term Sheet contempl [Showing first 8,000 characters — download PDF for full document]